

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**同方康泰產業集團有限公司**  
**Tongfang Kontafarma Holdings Limited**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1312)**

**ANNOUNCEMENT PURSUANT TO  
RULE 3.7 OF THE TAKEOVERS CODE  
END OF OFFER PERIOD  
UPDATE ON THE POSSIBLE TRANSACTION**

**INTRODUCTION**

This announcement is made by Tongfang Kontafarma Holdings Limited (the “**Company**”) pursuant to Rule 3.7 of The Code on Takeovers and Mergers of Hong Kong (the “**Takeovers Code**”).

Reference is made to the announcements of the Company respectively dated 8 May 2019, 6 June 2019, 5 July 2019, 6 August 2019 and 6 September 2019 (the “**Announcements**”) in relation to the Possible Transaction contemplated under the MOU entered into between Shenzhen Aorongxin and the Potential Purchaser. Unless otherwise specified, terms used in this announcement have the same meanings as those used in the Announcements.

**END OF OFFER PERIOD**

In relation to the application made for and on behalf of the Designated Entity to the Executive for a ruling that, if the Possible Transaction is to proceed, the Designated Entity will not be obliged to make a mandatory general offer to shareholders of the Company upon completion of the Possible Transaction pursuant to Note 8 to Rule 26.1 of the Takeovers Code, the Board was informed that a ruling has been obtained from the Executive on 30 September 2019 that no general offer will be required to be made for the Company as a result of the Possible Transaction under Note 8 to Rule 26.1 of the Takeovers Code.

Accordingly, the offer period in relation to the Possible Transaction, which commenced on 8 May 2019, ended on 30 September 2019. The Company will cease to publish further monthly announcements in respect of the progress of the Possible Transaction, which would otherwise be required under Rule 3.7 of the Takeovers Code.

## UPDATE ON THE POSSIBLE TRANSACTION

The Board also wishes to update the Company's shareholders and potential investors that, as informed by Mr. Huang, the negotiation between Shenzhen Aorongxin and the Designated Entity in respect of the definitive terms and the structure of the Possible Transaction is still in progress. Up to the date of this announcement, no formal or legally binding agreement has been entered into in respect of the Possible Transaction.

By order of the Board of  
**Tongfang Kontafarma Holdings Limited**  
**Huang Yu**  
*Chairman*

Hong Kong, 2 October 2019

*As at the date of this announcement, the Board comprises two executive Directors, namely Mr. Huang Yu (Chairman) and Mr. Jiang Chaowen (Chief Executive Officer); and three independent non-executive Directors, namely Mr. Chan Sze Chung, Mr. Zhang Ruibin and Mr. Zhang Junxi Jack.*

*The directors of the Company jointly and severally accept full responsibility for the accuracy of information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.*